Pfizer Unveils Promising Early Data On COVID-19, Sends Moderna Shares Down
Preliminary Results From 45 Subjects
Pfizer and BioNTech appear to have the upper hand on mRNA rivals Moderna, but Phase III results will be the real test.
You may also be interested in...
Phase I/IIa trial is poised to start in July versus a prior target of September, with a Phase III start targeted for late September. J&J also reported 2.1% pharma sales growth, reflecting an impact from COVID-19.
Delay to Moderna's Phase III plans adds to the biotech's rollercoaster ride, but its CEO insists it is still on track.
Partnering with AstraZeneca, the Oxford team has opened up a clear lead in the race to enrol thousands of patients for late-stage safety and efficacy trials – but cannot make guarantees of when results might be ready.